| Date | Title | Description |
| 16.09.2024 | PhoreMost: Biopharmaceutical Drug Target Company Raises $50 Million (Series B) | PhoreMost, a leading UK biopharmaceutical company unlocking the next generation of drug targets, announced it has added $12 million to its Series B financing, bringing the total raised to over $50 million. Parkwalk Advisors led this additio... |
| 11.09.2024 | PhoreMost Raises $12M in Series B; Extends Round to $50M | PhoreMost Ltd., a Cambridge, UK-based biopharmaceutical company, added USD $12m to its Series B financing, bringing the total raised to over $50m.
The additional investment was led by Parkwalk Advisors, with participation from existing inve... |
| 11.09.2024 | PhoreMost raises £33M to advance 'Drugging the Undruggable' research | PhoreMost, the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, has completed an oversubscribed £33 million Series B investment round.
PhoreMost’s SITESEEKER platform can identify the best new the... |
| 10.09.2024 | PhoreMost and Puraffinity: Two Biotech Innovators Making Waves in Healthcare | In the world of biotechnology, innovation is the lifeblood that fuels progress. Two companies, PhoreMost and Puraffinity, are leading the charge with groundbreaking advancements in drug development and environmental remediation. Both have r... |
| 10.09.2024 | PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes | Investment to enable progression of pipeline of novel degrader assets through pre-clinical development and support further development of GlueSEEKER™ platform
Led by Parkwalk Advisors alongside existing investors BGF, Dr Jonathan Milner, Am... |
| 08.09.2024 | Astellas Pharma: Cultivating Innovation in Life Sciences | Astellas Pharma Inc. is planting seeds of innovation in the heart of Cambridge, Massachusetts. The newly inaugurated Astellas Life Sciences Center (ALSC) is more than just a building; it’s a beacon for collaboration and creativity in the ph... |
| 05.09.2024 | Astellas Unveils New Life Sciences Center in Cambridge, Massachusetts to Accelerate the Discovery of Breakthrough Therapies | The Astellas Life Sciences Center hosts the company's first U.S.-based open innovation SakuLab™ incubator space dedicated to fostering pioneering science through collaboration with external partners
TOKYO and CAMBRIDGE, Mass., Sept. 5, 2024... |
| 04.09.2024 | Astellas to Present VEOZAH™ (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society | - Pooled analyses from two SKYLIGHT™ studies highlight impact on sleep disturbance and impairment, relationship between improvements in the frequency or severity of hot flashes and mood
- Pooled data from three SKYLIGHT™ studies assess safe... |
| 29.08.2024 | Nanoform Q2 report: All business targets for 2024 on track | Nanoform Q2 report: All business targets for 2024 on track
Thu, Aug 29, 2024 07:10 CET Report this content
Company Announcement
Nanoform Finland Plc
August 29, 2024
08:10 a.m. Finnish time / 07:10 a.m. Swedish time
Nanoform Q2 report: All b... |
| 27.08.2024 | Astellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy | - HIGHLIGHT 1™ study to evaluate fezolinetant for treatment of moderate to severe vasomotor symptoms in women with stage 0-3 hormone receptor positive breast cancer receiving adjuvant endocrine therapy -
TOKYO, Aug. 27, 2024 /PRNewswire/ --... |
| 26.08.2024 | Opna Bio Doses First Patient in Phase 1 Study in Multiple Myeloma with OPN-6602, an EP300/CBP Bromodomain Inhibitor | Appoints Axel Bolte, MBA, MSc, to Board Director and Stephanie Oestreich, PhD, MPA, to Board Observer
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–August 26, 2024–
Opna Bio announced that it has dosed the first patient with OPN-6602, a poten... |
| 12.08.2024 | Ocumension (01477.HK) Demonstrates Strong Operational Resilience, Commercialization Capabilities Reach New Heights | SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 12, Ocumension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "Ocumension" or the "Company") released its 2024 Interim Results Report. During the... |
| 12.08.2024 | Ocumension (01477.HK) Demonstrates Strong Operational Resilience, Commercialization Capabilities Reach New Heights | SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 12, Ocumension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "Ocumension" or the "Company") released its 2024 Interim Results Report. During the... |
| 28.07.2024 | New Frontiers in Cancer Treatment: Breakthroughs from Harbour BioMed and Astellas Pharma | In the relentless battle against cancer, innovation is the sword that cuts through despair. Two recent announcements from Harbour BioMed and Astellas Pharma illuminate the path forward, showcasing novel therapies that could reshape treatmen... |
| 26.07.2024 | Astellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer | - If approved by the European Commission, zolbetuximab would become the first and only CLDN18.2-targeted therapy approved in the European Union
- A decision on the EU marketing authorization is expected by October 2024
TOKYO, July 26, 2024 ... |
| 22.07.2024 | Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy | - Collaborative Research on Innovative Cartilage Organoid Cell Therapy for Intervertebral Disc Degenerative Disease using Astellas' Universal Donor Cell Technology -
TOKYO and OSAKA, Japan, July 22, 2024 /PRNewswire/ -- Astellas Pharma Inc.... |
| 30.05.2024 | Nanoform's biologics technology showcased by large pharma at drug delivery conference; Nanoenzalutamide and nanoapalutamide partnering discussions progress as planned | Nanoform's biologics technology showcased by large pharma at drug delivery conference; Nanoenzalutamide and nanoapalutamide partnering discussions progress as planned
Thu, May 30, 2024 07:10 CET Report this content
Company Announcement
Nano... |
| 13.05.2024 | Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting | 16 abstracts feature new data and post-hoc analyses of pivotal trials across several types of hard-to-treat cancers
TOKYO, May 13, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas")... |
| 07.05.2024 | Prevent Blindness to Host the 2024 ASPECT Patient Engagement and Advocacy Summit in Washington, D.C. | Prevent Blindness to host the 2024 ASPECT Patient Engagement and Advocacy Summit and Eyes on Capitol Hill event in Washington, D.C., May 14-16, 2024.
Three-day event brings together patients, care partners, and public health champions to ad... |
| 19.03.2024 | NVIDIA Healthcare Launches Generative AI Microservices for Drug Discovery | What You Should Know:
NVIDIA today launched more than two dozen new microservices that allow healthcare enterprises worldwide to take advantage of the latest advances in generative AI from anywhere and on any cloud.
The new suite of NVIDIA ... |
| 11.03.2024 | CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update | - CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 -
- CX-2051 (EpCAM ADC) Phase 1 clinical study initiation in solid tumors, including colorectal cancer (CRC) antici... |
| 26.02.2024 | Life Science Innovation Network Japan (LINK-J) “Pitch Contest for Research and Technology Seeds Leading to I nnovative Cancer Treatment” | - |
| 26.02.2024 | Life Science Innovation Network Japan (LINK-J) “Pitch Contest for Research and Technology Seeds Leading to I nnovative Cancer Treatment” | Life Science Innovation Network Japan (LINK-J)
“Pitch Contest for Research and Technology Seeds Leading to Innovative Cancer Treatment” – Recruiting viewers –
Five teams with oncology drug discovery seeds and technological ideas will compet... |
| 08.01.2024 | Regenerative Medicine Market Set to Hit USD 194.9 Billion by 2032, Driven by Robust CAGR of 19.4% | Continuous research and development in biotechnology, cell therapy, gene therapy, and tissue engineering are driving the industry forward. Breakthroughs in these areas can lead to new treatments and applications in regenerative medicine.
Ne... |
| 16.10.2023 | 見守りをもっと身近に。コミュニケーションロボット「BOCCO emo LTEレンタルモデル」を10月16日（月）提供開始 | 「ロボティクスで、世界をユカイに。」を掲げ、数多くのコミュニケーションロボットやIoTプロダクトを企画・開発するユカイ工学株式会社（本社：東京都新宿区、代表：青木 俊介）は、コミュニケーションロボット「BOCCO emo LTEレンタルモデル」の提供を2023年10月16日（月）より開始します。これまで要望の多かった「Wi-Fi環境が無い両親の家で使いたい」「初期費用の負担を抑えたい」というお客さまの声をもとに、BOCCO emo にLTE通信機能を搭載したモデルをレンタルで... |
| 11.10.2023 | アステラス製薬、BioLabs、三井不動産 つくばおよび柏の葉におけるライフサイエンス エコシステムの発展に向けた覚書を締結 | アステラス製薬株式会社（本社：東京中央区、代表取締役社長CEO：岡村 直樹、以下「アステラス製薬」）、BioLabs Global, Inc.（本社：米国マサチューセッツ州、Founder and CEO: Johannes Fruehauf、以下、「BioLabs」）、三井不動産株式会社（本社：東京中央区、代表取締役社長：植田 俊、以下、「三井不動産」）は、つくばおよび柏の葉におけるライフサイエンスエコシステムの発展に向けた覚書を締結しました。本覚書に基づき三社は、2023... |
| 12.05.2023 | FDA approves drug called Veozah to treat hot flashes resulting from menopause | The Food and Drug Administration announced Friday it has approved a new kind of drug to treat moderate to severe hot flashes caused by menopause, which could offer relief to millions of women who do not want to take hormone therapy to treat... |
| 01.05.2023 | Eying Its Next Blockbuster, Astellas Lines Up $5.9B Iveric Bio Acquisition | Astellas Pharma is hunting for drugs to make up for the decline in revenue facing its top-selling product as it loses patent protection in the next few years. It sees a strong contender in an Iveric Bio drug candidate for a common vision lo... |
| 21.02.2023 | Japanese corporations want to do business with European startups – here's how to get in on it | From Fujifilm to Mitsubishi, major Japanese corporations are looking to boost their innovations, and they're looking to Europe to do just that.
On March 7-9th, Japanese corporations will be reverse-pitching – presenting themselves to startu... |
| 25.01.2023 | Astellas Plots Near-Term Moves to Execute Long-Term Vision in Gene Therapy | Astellas sees gene therapy as a key part of its growth and it has been mapping out a strategy in this emerging therapeutic field even amid setbacks to its programs. Its two most advanced gene therapy candidates were under clinical holds for... |
| 04.01.2023 | Biotech investor Brad Loncar shares 10 predictions for 2023, including a hot new cancer target, Nobel Prize winners, and a biotech founder running for president | Brad Loncar, biotech investor and CEO of Loncar Investments Brad Loncar This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
For the third straight year with Insider, biotech investor Brad Lon... |
| 02.11.2022 | What causes hot flashes? Astellas ramps up educational campaign ahead of FDA decision | Astellas’ fezolinetant isn’t due for an FDA decision until February in vasomotor symptoms (VMS) associated with menopause — but the pharma company isn’t waiting until then to educate women about what’s causing their... |
| 04.10.2022 | Astellas, Pantherna add organ to mRNA tie-up; Rocket launches sale of six figures worth of stock | Astellas and Pantherna have expanded their November 2021 pact surrounding the latter’s mRNA platform to include a new target organ, the duo announced Tuesday morning, though they did not specify what that target is.
Ge... |
| 25.07.2022 | UKI2S gets £37m top up to support British energy, defence, biology spinouts | Publicly backed UK Innovation and Science Seed Fund (UKI2S) is expanding its patient capital fund by £37m to support spinouts in fields like synthetic biology, fusion energy and defence.
The evergreen fund — one with no set end date, which ... |
| 06.06.2022 | PADCEV™ (enfortumab vedotin) treatment for Locally Advanced or Metastatic Urothelial Cancer receives market authorisation in Singapore | Enfortumab vedotin is the first antibody drug conjugate approved in Singapore for la/mUC patients who received a prior platinum-containing chemotherapy and a PD-1/L1 inhibitor.
SINGAPORE – Media OutReach – 6 June 2022 – Astellas Pharma Inc.... |
| 01.06.2022 | Four years after Roche deal, little glyco-focused biotech lands new discovery deal with Astellas | Putting immuno-oncology front and center in its R&D strategy, Astellas has brought in a low-profile team to help hunt for its next wave of therapies.
Its partner of choice is a little biotech called GO Therapeutics, whos... |
| 08.02.2022 | Astellas Pharma : Announces Management Structure | Press Release
Astellas Announces Management Structure
TOKYO, February 8, 2022 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the following Top Management members effective ... |
| 08.02.2022 | Astellas Announces Positive Safety Data from the FORTIS Study of AT845 in Adults with Late-Onset Pompe Disease | TOKYO - Astellas Pharma Inc. (TSE: 4503, President and CEO:
Kenji Yasukawa, Ph.D., 'Astellas') announced positive interim safety data from FORTIS, the Phase I/II clinical trial evaluating AT845, an investigational adeno-associated virus (AA... |
| 02.02.2022 | Astellas Pharma : Announces Acquisition of Own Shares and Cancellation of Treasury Stock | - Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act and cancellation of treasury stock pursuant to the provisions of Article 178 of the Comp... |
| 24.01.2022 | Astellas Pharma : Meeting Script（3,989KB） | Astellas Pharma Inc.
Digital Transformation of Astellas Pharma
January 21, 2022
Event Summary
[Company Name] Astellas Pharma Inc. [Company ID] 4503-QCODE [Event Language] JPN [Event Name] Digital Transformation of Astellas Pharma
[Date] Jan... |
| 21.01.2022 | Astellas Pharma : Digital Transformation of Astellas Pharma（3,351KB） | DIGITAL TRANSFORMATION OF ASTELLAS PHARMA
Media Briefing - January 21, 2022
Cautionary Statement Regarding Forward-Looking Information 2
In this material, statements made with respect to current plans, estimates, strategies and beliefs and ... |
| 04.01.2022 | Responsum Health to Launch Innovative Menopause Platform to Inform and Empower Patients | As technology has evolved, the internet has made it easier for patients to independently research the disease; however, credibility, accuracy, and authority of the information they find are often lacking.
WASHINGTON (PRWEB) January 04, 2022... |
| 03.01.2022 | Will the Biden administration use ‘march-in’ to protect prostate cancer patients from excessive drug prices? | Astellas Pharma, a drug company headquartered in Japan, is charging U.S. patients $156,000 a year for the prostate cancer drug Xtandi (enzalutamide) — more than three to five times what it charges residents of other wealthy countries, and f... |
| 20.12.2021 | Astellas Pharma : and Seagen Receive Positive CHMP Opinion for PADCEV (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer | Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™
(enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
If approved, PADCEV would be the first medicine for patients in the EU who have received prior platinum-b... |
| 06.12.2021 | Astellas Pharma : Corporate Covernance Report | CORPORATE GOVERNANCE REPORT Astellas Pharma Inc. Date of last revision: December 6, 2021
Astellas Pharma Inc. Kenji Yasukawa Representative Director, President and CEO
Contact: Corporate Advocacy & Relations Tel: 03-3244-3201 Securities... |
| 06.12.2021 | Astellas Pharma : Corporate Governance Report | CORPORATE GOVERNANCE REPORT Astellas Pharma Inc. Date of last revision: December 6, 2021
Astellas Pharma Inc. Kenji Yasukawa Representative Director, President and CEO
Contact: Corporate Advocacy & Relations Tel: 03-3244-3201 Securities... |
| 06.12.2021 | Astellas Pharma : Applied for Selection of “Prime Market”segment of the Tokyo Stock Exchange | Press Release
Astellas Applied for Selection of "Prime Market"
segment of the Tokyo Stock Exchange
TOKYO, December 6 , 2021 - Astellas Pharma Inc. (TSE: 4503, President and
CEO: Kenji Yasukawa, Ph.D., "Astellas") today a... |
| 30.11.2021 | We published a story: “Patient centricity at Astellas—all about action.” | A team dedicated to patient centricity within a pharmaceutical company may seem redundant. After all, it should be a given that a company focused on drug discovery, development and delivery to address the health needs of patients would be, ... |
| 26.11.2021 | Astellas Pharma : Annual Report 2021 is now available. | Astellas publish its annual report as an integrated report to enable deeper stakeholder understanding of Astellas' efforts to continuously create value for sustainable growth.
Annual Report 2021 is now available at the following link:
https... |
| 26.10.2021 | Astellas Pharma : We published our corporate brand movie on the VISION section. | At Astellas, we are relentless in our pursuit of scientific progress and in identifying unmet medical needs by monitoring the changes in healthcare from multiple perspectives. We are committed to the realization of greater VALUE by patients... |
| 20.10.2021 | Astellas Pharma : Receives “2021 Award for Excellence in Corporate Disclosure” from the Securities Analysts Association of Japan | TOKYO, October 20, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that the company has ranked first in the pharmaceuticals sector for the "2021 Award for Excellen... |
| 13.10.2021 | Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV (enfortumab vedotin-ejfv) with Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer | TOKYO and BOTHELL, Wash. - Astellas Pharma Inc. (TSE:4503, President and CEO:
Kenji Yasukawa, Ph.D., 'Astellas') and Seagen Inc. (Nasdaq:SGEN) announced that patient enrollment was completed in Cohort K of the phase 1b/2 EV-103 clinical tri... |
| 08.10.2021 | Astellas joins the Milner Therapeutics Consortium | Astellas joins the Milner Therapeutics Consortium
08-10-2021
Astellas Pharma Inc has announced that it has joined the Milner Therapeutics Consortium, led by the Milner Therapeutics Institute (MTI), University of Cambridge.
The MTI was found... |
| 01.10.2021 | What to Know: Resuming Your Pre-Pandemic Routine With Overactive Bladder Symptoms | (BPT) - As vaccinations have become more widely available,[1] many people are starting to resume pre-pandemic activities.[2] For the 30 million Americans ages 40 and older impacted by overactive bladder or "OAB", [3] returning to ... |
| 30.09.2021 | Astellas Pharma : Corporate Strategic Plan 2021—dedicated to realization | Astellas' Corporate Strategic Plan 2021 (CSP2021) is charged with realizing the company's VISION of standing "on the forefront of healthcare change to turn innovative science into VALUE for patients." The plan shines a spotlight o... |
| 30.09.2021 | Astellas Pharma : announces the publication of New Contents related to its Corporate Strategic Plan 2021 and an Update to its About Section | This is to notify you that Astellas has published new contents related to its Corporate Strategic Plan 2021 (CSP2021) and updated its About section. 1．New Contents Related to CSP 2021
2 contents related to CSP 2021 have been published as be... |
| 28.09.2021 | Astellas Pharma : Japan's MHLW Approves PADCEV (enfortumab vedotin) for Advanced Urothelial Cancer | TOKYO and BOTHELL, Wash. - Astellas Pharma Inc. (TSE:4503, President and CEO:
Kenji Yasukawa, Ph.D., 'Astellas') and Seagen Inc. (Nasdaq:SGEN) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved PADCEV (enfortu... |
| 27.09.2021 | Astellas Pharma : Japan's MHLW Approves PADCEV (enfortumab vedotin) for Advanced Urothelial Cancer | Japan's MHLW Approves PADCEV® (enfortumab vedotin) for Advanced
Urothelial Cancer
Enfortumab vedotin is the first and only antibody-drug conjugate (ADC) approved in Japan for patients with advanced urothelial cancer -
TOKYO and BOTHELL, Was... |
| 20.09.2021 | Astellas Pharma : ' AND PFIZER'S XTANDI (ENZALUTAMIDE) REDUCED RISK OF DEATH BY 34% IN MEN WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER IN PHASE 3 ARCHES STUDY | TOKYO and NEW YORK - Astellas Pharma Inc. (TSE: 4503, President and CEO:
Kenji Yasukawa, Ph.D., 'Astellas') and Pfizer Inc. (NYSE: PFE) announced ahead of the European Society for Medical Oncology (ESMO) Congress 2021 that XTANDI (enzalutam... |
| 18.09.2021 | Pfizer : Astellas' and Pfizer's XTANDI® (enzalutamide) Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study | Late-breaking abstract to be presented September 18 during European Society for Medical Oncology Congress 2021
TOKYO and NEW YORK, September 17, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas') a... |
| 14.09.2021 | Astellas Reports Update to September 1 Announcement on the ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy | |
| 02.09.2021 | Nitto Denko : , Astellas, and M. Heart Partnering for ECG testing service | Press Release 2021
2021/Sep/02
Total Solution for Early Detection of Atrial Fibrillation Using Disposable Holter ECG device and AI-Based Analysis Service Nitto, Astellas, and M. Heart Partnering for ECG testing service
OSAKA, TOKYO and IWAT... |
| 01.09.2021 | Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy | |
| 31.08.2021 | Astellas Pharma : Announces Personnel Changes | Press Release
Astellas Announces Personnel Changes
TOKYO, August 31, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.) today announced that the personnel changes as below.
1. Change in the responsibility of C... |
| 31.08.2021 | Astellas Pharma : Launches its Corporate Website's New Modalities～Approach for Cell and Gene Therapies～ Section | We, at Astellas, are actively advancing new modalities/technologies based on our research and development strategy, the Focus Area Approach.
Here we introduce our initiatives on Cell and Gene Therapies -where we concentrate our R&D inve... |
| 20.08.2021 | FibroGen : Roxadustat is the first orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor available for adult patients with anemia associated with chronic kidney disease ... | Roxadustat is the first orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor available for adult patients with anemia associated with chronic kidney disease in Europe
TOKYO, August 19, 2021 - Astellas Pharma ... |
| 20.08.2021 | Astellas Pharma : Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease | TOKYO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced that th... |
| 20.08.2021 | Astellas Pharma : Receives EC Approval for First-inClass EVRENZO (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease | Press Release
Astellas Receives European Commission Approval for First-in-
Class EVRENZOTM (roxadustat) for Adult Patients with
Symptomatic Anemia of Chronic Kidney Disease
Roxadustat is the first orally administered hypoxia-inducible facto... |
| 18.08.2021 | Astellas Partners with LabCentral to Help Emerging Biotechs Accelerate Preclinical Scientific Research | |
| 09.07.2021 | U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer | |
| 28.06.2021 | Astellas Pharma : Receives Positive CHMP Opinion for EVRENZO (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease | Press Release
Astellas Receives Positive CHMP Opinion for EVRENZOTM (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
TOKYO, June 25, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji
Yasukawa,... |
| 25.06.2021 | FibroGen : Astellas Receives Positive CHMP Opinion for EVRENZOTM (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease (Form 8-K) | Astellas Receives Positive CHMP Opinion for EVRENZOTM (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
TOKYO, June 25, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., 'Astel... |
| 25.06.2021 | Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease | |
| 17.06.2021 | ASTELLAS PHARMA INC.
Astellas Pharma : Notice Regarding Impairment Loss Following the Termination of DNA Vaccine ASP0892 Development | Press Release
Notice Regarding Impairment Loss
Following the Termination of
DNA Vaccine ASP0892 Development
TOKYO, June 17, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced to... |
| 16.06.2021 | ASTELLAS PHARMA INC.
Astellas Pharma : Transfers Five Legacy Products in Europe, Russia, CIS and Asia to Cheplapharm | Press Release
Astellas Transfers Five Legacy Products
in Europe, Russia, CIS and Asia to Cheplapharm
TOKYO, June 16, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced tha... |
| 09.06.2021 | ASTELLAS PHARMA INC.
Astellas Pharma : New Research Reflects Astellas' Commitment to Acute Myeloid Leukemia at EHA 2021 Virtual Congress | TOKYO - Astellas Pharma Inc. (TSE: 4503, President and CEO:
Kenji Yasukawa, Ph.D., 'Astellas') announced the presentation of new data in acute myeloid leukemia (AML) at the European Hematology Association (EHA) virtual congress, taking plac... |
| 08.06.2021 | New Research Reflects Astellas' Commitment to Acute Myeloid Leukemia at EHA 2021 Virtual Congress | |
| 03.06.2021 | ASTELLAS PHARMA INC.
Astellas Pharma : Reviewing capabilities for sustainable growth - Astellas Will Offer an Early Retirement Incentive Program | Press Release
Reviewing capabilities for sustainable growth
- Astellas Will Offer an Early Retirement Incentive Program -
TOKYO, June 3, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas" ... |
| 20.05.2021 | ASTELLAS PHARMA INC.
Astellas Pharma : and Seagen Announce Updated Results from Two Trials of PADCEV (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not El... | TOKYO and BOTHELL, Wash. - Astellas Pharma Inc. (TSE: 4503, President and CEO:
Kenji Yasukawa, Ph.D., 'Astellas') and Seagen Inc. (Nasdaq:SGEN) announced updated results from two clinical trials examining PADCEV (enfortumab vedotin-ejfv) al... |
| 19.05.2021 | Astellas and Seagen Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemother... | |
| 18.05.2021 | ASTELLAS PHARMA INC.
Astellas to Present Data from Expanding Oncology Portfolio During the 2021 ASCO Annual Meeting | TOKYO - Astellas Pharma Inc. (TSE: 4503, President and CEO:
Kenji Yasukawa, Ph.D., 'Astellas') will share new data across its oncology portfolio during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, 2021... |
| 17.05.2021 | Astellas to Present Data from Expanding Oncology Portfolio During the 2021 ASCO Annual Meeting | |
| 13.05.2021 | Japan's Ministry of Health, Labour and Welfare Grants Priority Review for Enfortumab Vedotin New Drug Application | |
| 06.05.2021 | ASTELLAS PHARMA INC.
Astellas Pharma : ' XTANDI (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer | Press Release
Astellas' XTANDITM (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer
Enzalutamide is now the only oral therapy approved by the European Commission to
treat three distinct ... |
| 04.05.2021 | Astellas' XTANDI™ (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer | |
| 28.04.2021 | ASTELLAS PHARMA INC.
Astellas Pharma Inc. : - Change of Directors | TOKYO - Astellas Pharma Inc. (TSE: 4503, President and CEO:
Kenji Yasukawa, Ph.D., 'Astellas') announced that at a meeting of its Board of Directors held today, it decided a change in Directors as stated below. This change is subject to app... |
| 28.04.2021 | ASTELLAS PHARMA INC.
Astellas Pharma Inc. : - Notice Regarding Impairment Loss for Investigational Gene Therapy AT132 and the Differences Between Financial Forecasts and Actual Results for the Fiscal... | TOKYO - (TSE: 4503, President and CEO:
Kenji Yasukawa, Ph.D., 'Astellas') announced that it booked an impairment loss in the fourth quarter of the fiscal year ended March 31, 2021 (April 1, 2020 to March 31, 2021) and that there are differe... |
| 27.04.2021 | ASTELLAS PHARMA INC.
Astellas Pharma : Change of Directors | Press Release
Change of Directors
TOKYO, April 27, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that at a meeting of its Board of Directors held today, it decided a ... |
| 27.04.2021 | ASTELLAS PHARMA INC.
Astellas Pharma : Notice Regarding Impairment Loss for Investigational Gene Therapy AT132 and the Differences Between Financial Forecasts and Actual Results | Press Release
Notice Regarding Impairment Loss for Investigational Gene Therapy AT132 and the Differences Between Financial Forecasts and Actual Results
for the Fiscal Year Ended March 31, 2021
TOKYO, April 27, 2021 - Astellas Pharma Inc. (... |
| 20.04.2021 | ASTELLAS PHARMA INC.
Astellas Pharma : and Seagen Announce FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV | Astellas and Seagen Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
- Priority Review Granted with Action Date of Augu... |
| 20.04.2021 | ASTELLAS PHARMA INC.
Astellas Pharma : and Seagen Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV (enfortumab vedotin-ejfv) in Locally Advanced or Metastati... | TOKYO and BOTHELL, Wash. - Astellas Pharma Inc. (TSE: 4503, President and CEO:
Kenji Yasukawa, Ph.D., 'Astellas') and Seagen Inc. (Nasdaq:SGEN) today announced the U.S. Food and Drug Administration (FDA) filed two supplemental Biologics Lic... |
| 19.04.2021 | Astellas and Seagen Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer | |
| 05.04.2021 | ASTELLAS PHARMA INC.
Astellas Pharma : and TOA EIYO Announce Termination of Distribution Agreement | Press Release
Astellas and TOA EIYO Announce Termination of
Distribution Agreement
TOKYO, April 5, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji
Yasukawa, Ph.D., "Astellas" ) and TOA EIYO Ltd. (President: Atsuo ... |
| 01.04.2021 | ASTELLAS PHARMA INC.
Astellas Pharma : Announces Termination of Co-promotion with Viatris for Lipitor Tablets | Press Release
Astellas Announces Termination of Co-promotion with Viatris, Succession of Manufacturing and Marketing Approval, and Transfer of Distribution
for Lipitor® Tablets
TOKYO, April 1, 2021 - Astellas Pharma Inc. (TSE: 4503, Preside... |
| 01.04.2021 | ASTELLAS PHARMA INC.
Astellas Pharma : and TB Alliance Enter into a New Collaborative Research Agreement to Identify Lead Compounds for the Treatment of Tuberculosis | TOKYO and New York - Astellas Pharma Inc. (TSE: 4503, President and CEO:
Kenji Yasukawa, Ph.D., 'Astellas' ) and TB Alliance (President and CEO:
Mel Spigelman, M.D.), a non-profit organization dedicated to finding faster-acting and affordab... |
| 01.04.2021 | ASTELLAS PHARMA INC.
Astellas Pharma : Establishes ' Gene Therapies' as its Global Gene Therapy Center of Excellence | TOKYO - Astellas Pharma Inc. (TSE: 4503, President and CEO:
Kenji Yasukawa, Ph.D., 'Astellas' ) today announced that it will further integrate its wholly owned subsidiary, Audentes Therapeutics, and establish 'Astellas Gene Therapies' withi... |
| 31.03.2021 | Audentes Therapeutics Expands Mission, Becomes Astellas Gene Therapies | |
| 30.03.2021 | ASTELLAS PHARMA INC.
Astellas Pharma : ' XOSPATA Meets Overall Survival Endpoint in COMMODORE Trial | Press Release
Astellas' XOSPATA® (gilteritinib) Meets Overall Survival
Endpoint in COMMODORE Trial of Patients with Relapsed or Refractory Acute Myeloid Leukemia with a
FLT3 Mutation
- Confirmatory Phase 3 trial in China, other countries st... |
| 29.03.2021 | Astellas' XOSPATA® (gilteritinib) Meets Overall Survival Endpoint in COMMODORE Trial of Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation | |
| 26.03.2021 | European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin | |
